The Latest Breaking News from Boehringer Ingelheim

Costs of at least 350 branded medications, including vaccines against Covid-19, shingles and cancer treatment Ibrance, will reportedly be hiked

For decades, psychiatrists have treated psychosis as if it were separate conditions. People experiencing hallucinations and delusions might be diagnosed with schizophrenia, bipolar disorder, severe depression and related diagnoses, and receive completely different treatments based on diagnosis. But new research suggests this approach may be fundamentally flawed.

Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products.

In the fast-paced world of healthcare, where aging population and technological leaps are driving significant growth in the sector, which of the two medical stocks, Veeva Systems (VEEV) and Alcon Inc. (ALC), could emerge as the better prescription for your portfolio? Let's find out….

The controversial painkiller is being cited in a growing number of deaths in Spain despite warnings about dangerous side-effects

IBM is know for its huge developments in AI and quantum, and is now investigating applications outside of technology?

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

Here's a roundup of top developments in the biotech space over the last 24 hours:

 Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).